Trial · NCT07880080
Transcutaneous Cervical Vagus Nerve Stimulation for Primary Dysmenorrhea
NCT07880080, Not applicable, Not yet recruiting, Sinop University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Transcutaneous Cervical Vagus Nerve Stimulation for Primary Dysmenorrhea. Trials, record NCT07880080. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07880080
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Transcutaneous Cervical Vagus Nerve Stimulation for Primary Dysmenorrhea
- NCT number
- NCT07880080
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 70 participants, estimated
- Lead sponsor
- Sinop University
- Conditions
- Primary Dysmenorrhea (PD), Menstrual Pain
- Interventions
- Transcutaneous Cervical Vagus Nerve Stimulation, Sham Transcutaneous Cervical Vagus Nerve Stimulation
- First posted
- 2026-10-19
- Last updated
- 2026-10-19
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Menstrual Pain Intensity Assessed by the Numerical Rating Scale | Baseline (Day 1 before the first intervention) through Day 5 of the menstrual cycle | Menstrual pain intensity will be assessed using an 11-point Numerical Rating Scale (NRS) ranging from 0 (no pain) to 10 (worst imaginable pain). Higher scores indicate greater pain intensity. The change in menstrual pain intensity over the study period will be compared between the active tcVNS and sham groups. |
| Primary | Change in Multidimensional Menstrual Pain Assessed by the Short-Form McGill Pain Questionnaire | Baseline (Day 1 before intervention) and Day 3 after the final intervention | The Short-Form McGill Pain Questionnaire will be used to assess sensory and affective dimensions of menstrual pain. Fifteen pain descriptors are rated from 0 to 3, generating a total score ranging from 0 to 45. Higher scores indicate greater pain severity. The change in total score will be compared between the active tcVNS and sham groups. |
| Secondary | Change in Functional and Emotional Impact of Dysmenorrhea | Baseline (Day 1 before intervention) and Day 3 after the final intervention | The functional and emotional impact of dysmenorrhea will be assessed using the Functional and Emotional Measure of Dysmenorrhea. Higher scores indicate greater functional and emotional impairment associated with dysmenorrhea. Changes in scores will be compared between the active tcVNS and sham groups. |
| Secondary | Change in Anxiety Symptoms | Baseline (Day 1 before intervention) and Day 3 after the final intervention | Anxiety symptoms will be assessed using the Anxiety subscale of the Hospital Anxiety and Depression Scale (HADS-A). Scores range from 0 to 21, with higher scores indicating greater anxiety symptom severity. |
| Secondary | Change in Depressive Symptoms | Baseline (Day 1 before intervention) and Day 3 after the final intervention | Depressive symptoms will be assessed using the Depression subscale of the Hospital Anxiety and Depression Scale (HADS-D). Scores range from 0 to 21, with higher scores indicating greater depressive symptom severity. |
| Secondary | Change in Menstrual Symptom Severity | Baseline (Day 1 before intervention) and Day 3 after the final intervention | Menstrual symptoms including pelvic cramping, low back pain, headache, nausea, vomiting, diarrhea, constipation, fatigue, dizziness, sleep disturbance, irritability, and difficulty concentrating will be rated from 0 (none) to 3 (severe). Changes in symptom severity will be compared between groups. |
| Secondary | Change in Autonomic Function Assessed by Heart Rate Variability | Day 1 before intervention, immediately after the first intervention, and Day 3 after the final intervention | Autonomic function will be assessed using standardized 5-minute RR interval recordings obtained with a Polar H10 chest strap. Recordings will be analyzed using Kubios HRV software. Heart rate variability parameters will include RMSSD, SDNN, LF/HF ratio, and mean heart rate. Changes in these parameters over time will be compared between the active tcVNS and sham groups. |
| Secondary | Analgesic Use During Menstruation | Daily from Day 1 through Day 5 of the menstrual cycle | Use of analgesic medication will be recorded daily, including medication name, dose, and time of administration. Analgesic use will be compared between the active tcVNS and sham groups. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers3
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07880080
GET https://conductscience.org/api/trials/v1/NCT07880080/registered